In order to understand how the diabetes drug Actos affects those who take it, researchers compared the side effects that occur with the use of Actos with how those who don’t take it fare. Medical studies done in the United States, United Kingdom, and France have all concluded that those who take Actos are far more likely to get bladder cancer than those who don’t take it.
Researchers also discovered that Actos users were up to 83 percent more likely to develop bladder cancer after using Actos for a period of more than two years. The report also indicated that the incidence rates of bladder cancer in patients taking Actos increased the longer the drug was taken.
Incidence Rates of Bladder Cancer
Medical studies observed users of Actos for a period of 12 months, 24 months, and longer, and what they found was that the patients’ risk of bladder cancer increased from approximately 30% after one year to as much as 83% percent after two years.
Currently, a 10-year study of Actos is ongoing and will come to a conclusion in 2013. This is the longest study tracking the drug and expected to provide the most accurate information about this type 2 diabetes medication. Among the findings to date:
No significant increase in less than 12 months of Actos use.
30 percent increased risk of bladder cancer with 12 to 24 months of use.
50 percent increased risk of bladder cancer with more than 24 months of use.
A greater than 50 percent risk of bladder cancer in those who use Actos for more than 48 months.
While the study does show that the longer one uses Actos the greater risk they have for developing bladder cancer, the true long-term effect will not be known until the 10-year study concludes and releases its final results.